Press Release

April 1, 2026

Press Release

Calidi Biotherapeutics to Present New Data on Its Differentiated Approach to In Situ T-Cell Engagers Including a New Candidate Targeting TROP-2 at the AACR Annual Meeting in April 2026

Calidi Biotherapeutics to Present New Data on Its Differentiated Approach to In Situ T-Cell Engagers…

March 24, 2026

Press Release

Calidi Biotherapeutics Announces Partnership with Avance Clinical to Facilitate Australian Regulatory Approval and Accelerate Initiation of CLD-401 Clinical Trials

Calidi Biotherapeutics Announces Partnership with Avance Clinical to Facilitate Australian Regulatory Approval and Accelerate Initiation…

March 12, 2026

Press Release

Calidi Biotherapeutics Presents its Innovative and Scalable Manufacturing Process for CLD-401 at the 9th Annual Bioprocessing Summit; FDA Feedback Support Company’s Approach to Manufacturing

Calidi Biotherapeutics Presents its Innovative and Scalable Manufacturing Process for CLD-401 at the 9th Annual…

March 9, 2026

Press Release

Calidi Biotherapeutics Announces Closing of $6.0 Million Underwritten Public Offering and Full Exercise of Underwriters’ Over-Allotment Option

Calidi Biotherapeutics Announces Closing of $6.0 Million Underwritten Public Offering and Full Exercise of Underwriters’…

March 5, 2026

Press Release

Calidi Biotherapeutics Announces Proposed Public Offering

Calidi Biotherapeutics Announces Proposed Public Offering SAN DIEGO, March 05, 2026 (GLOBE NEWSWIRE) — Calidi…

February 20, 2026

Press Release

Calidi Biotherapeutics Presents Data on its New Approach to Bispecific T-Cell Engagers (BiTEs) Using its RedTail Platform at the 2026 AACR-IO Conference

Calidi Biotherapeutics Presents Data on its New Approach to Bispecific T-Cell Engagers (BiTEs) Using its…

February 12, 2026

Press Release

Calidi Biotherapeutics To Present on its New Approach to Bispecific T-Cell Engagers (BiTEs) Using its RedTail Platform in a Late-Breaking Abstract at the 2026 AACR-IO Conference

Calidi Biotherapeutics To Present on its New Approach to Bispecific T-Cell Engagers (BiTEs) Using its…

January 28, 2026

Press Release

Calidi Biotherapeutics Provides Corporate Update and Key Value Drivers for 2026

Calidi Biotherapeutics Provides Corporate Update and Key Value Drivers for 2026 Company intends to file…

November 10, 2025

Press Release

Calidi Biotherapeutics Presents New Data on its Therapeutic Lead, CLD-401, at the 2025 SITC Annual Meeting and Holds Its First Investor Day at SITC

Calidi Biotherapeutics Presents New Data on its Therapeutic Lead, CLD-401, at the 2025 SITC Annual…

November 4, 2025

Press Release

Calidi Biotherapeutics Announces Investor Event to be Held on Friday, November 7th at the 2025 SITC Annual Meeting

Calidi Biotherapeutics Announces Investor Event to be Held on Friday, November 7th at the 2025…

October 30, 2025

Press Release

Calidi Biotherapeutics Announces New Data to be Presented on its Therapeutic Lead, CLD-401, at the 2025 SITC Annual Meeting

Calidi Biotherapeutics Announces New Data to be Presented on its Therapeutic Lead, CLD-401, at the…

October 22, 2025

Press Release

Calidi Biotherapeutics Announces Establishment of Scientific Advisory Board to Support Development of CLD-401 and Advance its RedTail Platform for the Systemic Delivery of Targeted Genetic Medicine

Calidi Biotherapeutics Announces Establishment of Scientific Advisory Board to Support Development of CLD-401 and Advance…

September 29, 2025

Press Release

Calidi Biotherapeutics to Present at the second annual Oncology Venture, Innovation, and Partnering Summit in Boston

Calidi Biotherapeutics to Present at the second annual Oncology Venture, Innovation, and Partnering Summit in…

September 2, 2025

Press Release

Calidi Biotherapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Calidi Biotherapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference SAN…

August 21, 2025

Press Release

Calidi Biotherapeutics Announces Closing of $6.9 Million Underwritten Public Offering and Full Exercise of Underwriters’ Over-Allotment Option

Calidi Biotherapeutics Announces Closing of $6.9 Million Underwritten Public Offering and Full Exercise of Underwriters’…

August 20, 2025

Press Release

Calidi Biotherapeutics Announces Pricing of $6 Million Underwritten Public Offering

Calidi Biotherapeutics Announces Pricing of $6 Million Underwritten Public Offering SAN DIEGO, CA., August 20,…

August 8, 2025

Press Release

Calidi Biotherapeutics Reports Second Quarter 2025 Financial Results and Recent Operational Highlights

Presented preclinical data at the American Society of Clinical Oncology (ASCO) on CLD-401 demonstrating biological…

July 29, 2025

Press Release

Calidi Biotherapeutics Receives FDA Fast Track Designation for CLD-201 (SuperNova), a First-In-Class Stem-Cell Loaded Viral Therapy for the Treatment of Patients with Soft Tissue Sarcoma

Calidi Biotherapeutics Receives FDA Fast Track Designation for CLD-201 (SuperNova), a First-In-Class Stem-Cell Loaded Viral…

July 25, 2025

Press Release

Calidi announces Reverse Stock Split, expected to begin trading on a 1-for-12 split adjusted basis on August 5, 2025

Calidi announces Reverse Stock Split, expected to begin trading on a 1-for-12 split adjusted basis…

July 9, 2025

Press Release

Calidi Biotherapeutics Announces Exercise of Warrants for $4.6 Million of Gross Proceeds

Calidi Biotherapeutics Announces Exercise of Warrants for $4.6 Million of Gross Proceeds SAN DIEGO,…

Press Release

Calidi Biotherapeutics to Present New Data on Its Differentiated Approach to In Situ T-Cell Engagers Including a New Candidate Targeting TROP-2 at the AACR Annual Meeting in April 2026

Calidi Biotherapeutics Announces Partnership with Avance Clinical to Facilitate Australian Regulatory Approval and Accelerate Initiation of CLD-401 Clinical Trials

Calidi Biotherapeutics Presents its Innovative and Scalable Manufacturing Process for CLD-401 at the 9th Annual Bioprocessing Summit; FDA Feedback Support Company’s Approach to Manufacturing

Calidi Biotherapeutics Announces Closing of $6.0 Million Underwritten Public Offering and Full Exercise of Underwriters’ Over-Allotment Option

Calidi Biotherapeutics Announces Proposed Public Offering

Calidi Biotherapeutics Presents Data on its New Approach to Bispecific T-Cell Engagers (BiTEs) Using its RedTail Platform at the 2026 AACR-IO Conference

Calidi Biotherapeutics To Present on its New Approach to Bispecific T-Cell Engagers (BiTEs) Using its RedTail Platform in a Late-Breaking Abstract at the 2026 AACR-IO Conference

Calidi Biotherapeutics Provides Corporate Update and Key Value Drivers for 2026

Calidi Biotherapeutics Presents New Data on its Therapeutic Lead, CLD-401, at the 2025 SITC Annual Meeting and Holds Its First Investor Day at SITC

Calidi Biotherapeutics Announces Investor Event to be Held on Friday, November 7th at the 2025 SITC Annual Meeting

Calidi Biotherapeutics Announces New Data to be Presented on its Therapeutic Lead, CLD-401, at the 2025 SITC Annual Meeting

Calidi Biotherapeutics Announces Establishment of Scientific Advisory Board to Support Development of CLD-401 and Advance its RedTail Platform for the Systemic Delivery of Targeted Genetic Medicine

Calidi Biotherapeutics to Present at the second annual Oncology Venture, Innovation, and Partnering Summit in Boston

Calidi Biotherapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Calidi Biotherapeutics Announces Closing of $6.9 Million Underwritten Public Offering and Full Exercise of Underwriters’ Over-Allotment Option

Calidi Biotherapeutics Announces Pricing of $6 Million Underwritten Public Offering

Calidi Biotherapeutics Reports Second Quarter 2025 Financial Results and Recent Operational Highlights

Calidi Biotherapeutics Receives FDA Fast Track Designation for CLD-201 (SuperNova), a First-In-Class Stem-Cell Loaded Viral Therapy for the Treatment of Patients with Soft Tissue Sarcoma

Calidi announces Reverse Stock Split, expected to begin trading on a 1-for-12 split adjusted basis on August 5, 2025

Calidi Biotherapeutics Announces Exercise of Warrants for $4.6 Million of Gross Proceeds

Company

Science

Legal